TuHURA Biosciences, Inc./NV earns about -629% on equity, but has diluted owners by 2858% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below. Whether it’s worth owning at today’s price is the last question — and yours to answer, below.
| Figure | FY 2023 | FY 2023 | FY 2024 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | — | $01 | — | $02 | $02 |
| Net income | −$14.6M3 | −$29.3M4 | −$8.32M3 | −$21.7M5 | −$30.1M5 |
| Operating cash flow | −$11.9M6 | −$12M7 | −$7.18M6 | −$14.7M8 | −$27.6M8 |
| Capital expenditure | — | $79,2249 | — | $57,90610 | $76,08310 |
| Free cash flow (derived) | — | −$12M7,9 | — | −$14.8M8,10 | −$27.7M8,10 |
| Total debt | — | — | — | — | — |
| Cash & equivalents | $1.54M11 | $3.67M12 | $4.91M11 | $12.7M13 | $3.62M13 |
| Diluted shares | 1.6M | 11.9M | 26.4M | 18.7M | 47.9M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom). A derived or summed figure cites every filing line it was built from.
10 shares is a claim on $4.37 of net worth that earned you −$6.27 and generated −$5.78 of cash last year.
It earned an average -629% on equity over 5 years. Compare that to what it costs to fund the business.
seeing a moat in the numbers →Share count is up 2858% over 5 years — owners have been diluted. Worth asking what they got for it.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
This page is free, and so is every other company on MeritValue.
Connect the MeritValue MCP server to Claude or another MCP client, ask about TuHURA Biosciences, Inc./NV, and get these exact figures with their filing receipts — not an improvised DCF.
Get a free key →Pull the companies with a published value under any model (up to 500 a request, filtered by data completeness) into your own sheet or agent. Screening is what Analyst adds, at $9/month.
See pricing →Follow HURA and keep your own price beside the value. The same engine, with the same receipts.
MeritValue on the App Store →- 10-K filed 2025-03-31 · period ending 2023-12-31 · accession 0000950170-25-047921 (Revenues)
- 10-K filed 2026-03-31 · periods ending 2024-12-31, 2025-12-31 · accession 0001193125-26-134950 (Revenues)
- 10-K filed 2024-10-07 · periods ending 2023-06-30, 2024-06-30 · accession 0000950170-24-113321 (NetIncomeLoss)
- 10-K filed 2025-03-31 · period ending 2023-12-31 · accession 0000950170-25-047921 (NetIncomeLoss)
- 10-K filed 2026-03-31 · periods ending 2024-12-31, 2025-12-31 · accession 0001193125-26-134950 (NetIncomeLoss)
- 10-K filed 2024-10-07 · periods ending 2023-06-30, 2024-06-30 · accession 0000950170-24-113321 (NetCashProvidedByUsedInOperatingActivities)
- 10-K filed 2025-03-31 · period ending 2023-12-31 · accession 0000950170-25-047921 (NetCashProvidedByUsedInOperatingActivities)
- 10-K filed 2026-03-31 · periods ending 2024-12-31, 2025-12-31 · accession 0001193125-26-134950 (NetCashProvidedByUsedInOperatingActivities)
- 10-K filed 2025-03-31 · period ending 2023-12-31 · accession 0000950170-25-047921 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K filed 2026-03-31 · periods ending 2024-12-31, 2025-12-31 · accession 0001193125-26-134950 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K filed 2024-10-07 · periods ending 2023-06-30, 2024-06-30 · accession 0000950170-24-113321 (CashAndCashEquivalentsAtCarryingValue)
- 10-K filed 2025-03-31 · period ending 2023-12-31 · accession 0000950170-25-047921 (CashAndCashEquivalentsAtCarryingValue)
- 10-K filed 2026-03-31 · periods ending 2024-12-31, 2025-12-31 · accession 0001193125-26-134950 (CashAndCashEquivalentsAtCarryingValue)